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ABSTRACT
Background and Objectives: Basal septal thinning or localized aneurysmal dilatation without coronary artery disease has 
been described as a characteristic finding suggestive of cardiac sarcoidosis. We sought to assess the prevalence of this charac-
teristic echocardiographic finding in patients with pacemaker (PM) or implantable cardiac defibrillator (ICD). Subjects and 
Methods: Echocardiography of patients who received PM or ICD were retrospectively analyzed. Patients with marked thin-
ning and akinesia confined to the basal septum (type 1), or posterolateral wall resulting in localized aneurysmal outward bulg-
ing (type 2) without history of myocardial infarction or significant coronary stenosis were included for analysis. Results: 
Among 1,357 consecutive patients, 21 exhibited suggestive echocardiographic findings (type 1/2=15/6) with a mean ejec-
tion fraction of 37±11%. The prevalence was 1.2% in the PM group and 4.0% in the ICD group. Only 3 patients showed his-
tologically confirmable sarcoidosis in lymph nodes, lung and heart, respectively. Endomyocardial biopsy was attempted in 6 
patients, but failed to demonstrate sarcoidosis. The 1-, 2-, 4- and 6-year clinical events (death, cardiac transplantation and hos-
pital admission)-free survival rates were 100%, 85.7±7.6%, 75.0±9.7% and 48.6±12.4%, respectively. During follow-up, two 
patients with PM underwent ICD implantation, and another underwent heart transplantation. Conclusion: Prevalence of 
echocardiographic features suggesting prevalence of cardiac sarcoidosis is low in patients who underwent device implanta-
tion. However, considering the very low yield of endomyocardial biopsy and the rare extracardiac manifestations in cardiac 
sarcoidosis, characteristic echocardiographic findings could be an adjunctive diagnostic criterion in these patients. (Korean 
Circ J 2011;41:313-320)
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Introduction
Sarcoidosis is a multi-systemic disease characterized by 
the formation of cryptogenic granulomas in a variety of tis-
sues.
1) The prevalence of cardiac involvement was reported 
in USA is approximately 20-27% of sarcoid patients, but has 
been reported to be as high as 58% in Japan.
2) The clinical ma-
nifestation of cardiac involvement is non-specific, and can in-
clude various degrees of atrio-ventricular block, ventricular 
arrhythmia, congestive heart failure, or even sudden cardiac 
arrest as an initial manifestation.
Diagnosis of cardiac sarcoidosis remains challenging, as pre-
vious studies reported that the sensitivity of endomyocardial 
biopsy, the gold standard for definitive diagnosis, is only 20-
30%.
2)3) Although patchy pathologic involvement is frequent 
and does not necessarily accompany any prominent morpho-
logical changes, several characteristic morphological chang-
es have been observed in advanced cases with cardiac sarcoido-
sis. The most common characteristic change is localized wall 
thinning involving the basal interventricular septum, which 
was seen in more than 90% of patients with cardiac sarcoid-314   Cardiac Sarcoidosis
osis.
4-6) Ventricular aneurysm, especially in the infero-poste-
rior wall, has been reported to be another characteristic find-
ing of cardiac sarcoidosis.
7) Thus, a combination of clinical fe-
atures and morphologic changes can form the basis for sc-
reening high risk patients. The screening of suspected cases 
of cardiac sarcoidosis is necessary in order to characterize pa-
tients with relatively high risk of cardiac abnormalities such 
as conduction disturbances, ventricular arrhythmias, and sud-
den arrest, particularly when these condition cannot be ex-
plained by other causes.
4) The principal aims of the present 
study were to evaluate the prevalence of echocardiographic 
findings suggestive of cardiac sarcoidosis in patients with 
conduction abnormalities or ventricular arrhythmias, and to 
describe the clinical characteristics of these patients.
Subjects and Methods
Study populations
We focus on screening patients with conduction abnorma-
lities or ventricular arrhythmia, and targeted patients who 
had received device therapy for arrhythmia, including perma-
nent pacemaker (PM) or implantable cardioverter-defibril-
lator (ICD). We screened the echocardiographic images of a 
total of 1,184 patients who had received PMs between Janu-
ary 1989 and December 2007, and 173 patients who had re-
ceived an ICD between January 1996 and December 2007 at 
the Asan Medical Center, Seoul, the Republic of Korea. Pa-
tients who showed typical morphologic changes suggestive 
of cardiac sarcoidosis on echocardiography, and who fulfill-
ed the diagnostic criteria according to the guidelines publi-
shed by the Japanese Ministry of Health and Welfare
8) were 
included for analysis. Exclusion criteria were established to ex-
clude the possibility of ischemic heart disease, as follow: 1) 
past medical history of documented myocardial infarction; 
2) definite electrocardiography or laboratory abnormalities 
with chest pain episode; 3) significant stenosis on coronary 
angiogram. However, as nonspecific perfusion defects can be 
noted on myocardial perfusion scan in cases of cardiac sarcoi-
dosis,
9)10) patients who showed abnormalities on thallium-201 
scintigraphy alone were not excluded. The study protocol was 
approved by the ethics committee of our institution, and inform-
ed consent was obtained from each patient at study entry.
Clinical and echocardiographic data
Two types of morphologic changes on echocardiography 
were considered characteristic morphologic changes sugges-
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Fig. 1. Representative echocardiographic images suggestive of cardiac involvement of sarcoidosis. Type 1 morphologic change is charac-
terized by thinning and akinesia of the basal septum (A and B). Aneurysmal dilatation involving inferior or posterolateral wall is classified as 
type 2 (C and D).Byung Joo Sun, et al.   315
tive of cardiac involvement of sarcoidosis (Fig. 1). Type 1 was 
characterized by thinning and akinesia of the basal septum 
at either parasternal long-axis or apical views (Fig. 1A and 
B). Aneurysmal dilatation involving the inferior or postero-
lateral wall was classified as type 2 (Fig. 1C and D). Clinical 
events were defined as any adverse clinical events, including 
death, cardiac transplantation, and hospital admission due to 
cardiac causes during the follow-up period following device 
implantation. For statistical analysis, we used non parametric 
methods for categorical and continuous variables. Event rates 
(±SE) were calculated according to the Kaplan-Meier method, 
with all clinical events by time to first event, and compared 
those with log-rank test. All p was two sided, and p<0.05 was 
considered to be statistically significance. Statistical Package 
for the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, 
IL, USA) was used for statistical analysis.
Results
Prevalence
In 1,184 patients who had received a PM, 214 patients (18.1%) 
exhibited regional wall motion abnormalities on echocardio-
graphy. Among them, 14 patients showed echocardiographic 
findings suggestive of cardiac sarcoidosis, and thus the prev-
alence was 1.2% (14/1,184). Among 173 patients who rec-
eived ICD, 71 (41.0%) patients exhibited regional wall mo-
tion abnormalities, of whom 7 had echocardiographic find-
ings suggestive of cardiac sarcoidosis. The estimated preval-
ence was 4.0% (7/173).
Representative images of two cases of cardiac sarcoidosis 
(case 10 and 14 in Table 1) were illustrated in Figs. 2 and 3. The 
first case (case 10) (Fig. 2) is a 53-year old male patient who un-
derwent PM implantation in 2003 due to complete atrio-ven-
tricular block. Since early 2007, progressive dysphasia develop-
ed and chest computed tomography revealed multiple lym-
phadenopathy in the mediastinum. He was referred to our hos-
pital with a suspected diagnosis of lymphoma. Biopsy of a su-
praclavicular lymph node revealed non-caseating granuloma 
with negative Ziehl-Neelsen and d-PAS staining consistent with 
sarcoidosis. Echocardiography showed typical thinning of the 
basal septum, with ejection fraction of 42%. Systemic sarcoi-
dosis with cardiac involvement was the final diagnosis and 
prednisolone 60 mg a day was prescribed, which was tapered 
to 5 mg during follow-up.
Table 1. Clinical characteristics of patients
Case 
no
Sex/
Age
Device
Echo
type
LVEF
(%)
CAG
Organ 
involvement
Endomyocardial 
biopsy
Steroid
use
Clinical event
01 M/56 Pacemaker I 33 Not done Heart only Not done None RFCA d/t atrial flutter
02 F/55 Pacemaker I 16 Not done Heart only Not done None CHF
03 F/51 Pacemaker I 44 Normal Heart only Not done None None
04 M/49 Pacemaker II 34 Normal Heart only Not done None Death*
05 M/64 Pacemaker I 25 Normal Heart only Not done None Death†
06 F/65 Pacemaker I 66 Not done Heart only Not done None CHF
07 F/43 Pacemaker I 45 Normal Heart only Negative result None None
08 M/50 Pacemaker I 39 Not done Heart only Not done None RFCA d/t atrial flutter
09 M/34 Pacemaker I 32 Not done Heart only Not done None None
10 M/53 Pacemaker I 42 Not done Heart; SCLN‡ Not done Yes None
11 M/48 Pacemaker I 36 Normal Heart only Not done None ICD insertion d/t VT
12  F/57 Pacemaker I 52 Normal Heart; Lung§ Not done Yes ICD insertion d/t VT
13 M/63 Pacemaker I 29 Normal Heart only Not done None CHF
14 M/44 Pacemaker I 38 Normal Heart only|| Tried but failed Yes Heart transplantation
15 M/56 ICD II 19 Normal Heart only Negative result None None
16 M/42 ICD II 34 Normal Heart only Not done None RFCA d/t VT
17 F/41 ICD II 40 Normal Heart only Negative result None None
18 F/43 ICD II 38 Normal Heart only Negative result Yes None
19 F/69 ICD I 35 Normal Heart only Not done None CHF
20 M/73 ICD I 37 Normal Heart only Not done None None
21 M/65 ICD II 38 Normal Heart; Liver Negative result Yes None
*
†Each patient No 4 and 5 died from gastrointestinal bleeding and intractable heart failure, respectively, ‡ § ||Each patient No 10, 12 and 14 ev-
idenced sarcoid granuloma on the specimen of SCLN, Lung and Heart, respectively. LVEF: left ventricular ejection fraction, CAG: coronary 
angiography, SCLN: supraclavicular lymph node, RFCA: radio-frequency catheter ablation, ICD: implantable cardioverter-defibrillator, VT: 
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The second case (case 14) (Fig. 3) was a 44-year old male who 
underwent PM implantation due to complete atrio-ventric-
ular block in 2005. Progressive dyspnea developed since early 
in 2006 and radiofrequency ablation was performed for atri-
al flutter in December 2006. The patient’s condition deterio-
rated rapidly despite receiving maximum medical therapy for 
congestive heart failure. Follow-up echocardiography show-
ed progressive thinning of the basal septum. Systemic work-
up failed to demonstrate any non-cardiac involvement of sa-
rcoidosis. Endomyocardial biopsy was attempted in Septem-
ber 2007 but failed to demonstrate any evidence of cardiac 
sarcoidosis. Prednisolone 60 mg a day was administered, wh-
ich was not effective to control his symptoms. He underwent 
successful cardiac transplantation in April 2008, and histology 
showed typical non-caseating granuloma suggesting cardiac 
sarcoidosis.
Clinical features
Clinical data of 21 patients whose echocardiographic find-
ings suggested cardiac involvement of sarcoidosis are sum-
marized in Table 1. Patients were aged between 34 to 73 years, 
with a mean age of 53.8±10.3 years when the device was im-
planted. Among 14 patients who received PMs, 11 patients pre-
sented with complete atrioventricular block, and the remain-
ing patients with trifascicular block (case 5), sinus bradycar-
dia (case 6) and junctional bradycardia (case 9). All 7 patients 
who received ICD presented with ventricular tachycardia.
Clinical manifestation before device implantation was vari-
able. Nine patients presented with dyspnea. Among them, 
the most indolent case aggravated gradually over 14 years 
(case 19). In contrast, in another case without previous ab-
normality, dyspnea aggravated rapidly just over 2 weeks 
(case 6). The time interval between the initial symptom and de-
vice implantation was relatively short in patients who devel-
oped syncope as presenting symptom, and 2 patients receiv-
ed device implantation after 1 week (case 16) and 1 month 
(case 18) after the initial episode, respectively. On the other 
hand, in 4 patients with dizziness (case 8, 10, 13, 14), the time 
interval between initial symptom and device implantation 
was as long as 1 year in all 4 cases.
Although all 7 patients who underwent ICD implantation 
were uniformly diagnosed with VT, the initial manifestation 
A  
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Fig. 2. (A) and (C) are computed tomographic images of a 53-year old patient those demonstrate numerous enlarged lymph nodes com-
pressing the adjacent structures. (B) is the echocardiographic image in which the arrow points at the basal septum with thinning. Panel D is 
a micrograph of a supraclavicular lymph node with non-caseating granuloma (hematoxylin and eosin stain, 200×; Scale bar=100 µm).Byung Joo Sun, et al.   317
was also variable. Two indolent cases manifested as recurrent 
palpitation over 7 (case 21) and 9 years (case 20), respectively. 
On the other hand, the most violent case was a 41 year-old 
woman (case 17), who had been healthy complained of epi-
gastric discomfort during breakfast, and, developed cardiac 
arrest immediately after as the initial manifestation.
The mean left ventricular ejection fraction was 37±11%. 
Among 21 patients of the study group, 15 patients (71%) sh-
owed type 1 echocardiographic features. In patients who had 
received PM implantation, echocardiographic type I finding 
was more predominant than in those with ICD {92.8% (13/ 
14) vs. 28.6% (2/7), p≤0.01}. Coronary angiography was per-
formed in 15 patients, which revealed normal findings. In 12 
patients, thallium-201 scintigraphy was conducted and ab-
normal perfusion was noted in 10 cases. However, among 
them, with the exception of a patient who did not undergo co-
ronary angiography, 9 patients revealed normal coronary an-
giographic findings.
Endomyocardial biopsy was attempted in 6 patients, but 
cardiac sarcoidosis was not demonstrated in any of these cas-
es. Among them, one patient (case 14) subsequently under-
went cardiac transplantation due to intractable heart failure, 
and non-caseating granuloma suggesting sarcoidosis was his-
tologically proven on the extracted heart. In addition to this, 
2 patients experienced sarcoidosis involvement of the lungs 
(case 12) and lymph nodes (case 10).
Although 21 patients showed characteristic echocardiogra-
phic findings suggestive of sarcoidosis, only 3 patients (14.3%) 
showed typical extracardiac involvement of sarcoidosis. Each 
of these patients (case 10, 12 and 21) revealed typical sarcoid 
involvement in the lungs, lymph nodes and liver, respectively.
Clinical events during follow-up
During follow-up (mean 75±18 months), various clinical 
events occurred. Nine patients (42.9%) had no adverse clini-
cal events, whereas the other 12 patients needed hospital ad-
mission due to cardiac causes. Four patients suffered from 
bouts of aggravated heart failure, five arrhythmic event, one he-
art transplantation. Two patients died during follow-up (Ta-
ble 1). Among them, 2 patients who had undergone PM im-
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Fig. 3. A 44-year old man who had undergone pacemaker insertion 2 years before due to complete atrio-ventricular block complained of re-
current palpitation and dyspnea. He was diagnosed with atrial flutter and received radiofrequency catheter ablation. (A) Thereafter, thinning 
of basal septum became more prominent while symptoms of heart failure are more aggravated over the next 16 months. (C) denotes the 
echocardiography at the time of heart transplantation. (D) is a micrograph showing non-caseating granuloma from tricuspid valve of extract-
ed heart (hematoxylin and eosin stain, 200×; Scale bar=100 µm).318   Cardiac Sarcoidosis
plantation (case 11 and 12), developed VT 7 and 5 years later, 
respectively and eventually underwent ICD implantation. 
Three patients (case 1, 8 and 14) who had already received PM 
implantation subsequently developed atrial flutter, hence 
they underwent radiofrequency catheter ablation. In one pa-
tient with ICD for VT (case 16), repeated ICD discharge was 
not prevented with medication. So that he underwent catheter 
ablation. One patient underwent cardiac transplantation due 
to intractable heart failure (case 14), and two patients died 
during follow-up. The cause of death was heart failure (case 5) 
and gastrointestinal bleeding (case 4), respectively. The 1-, 2- 
4-, and 6-year event-free survival rates were 100%, 85.7± 
7.6%, 75.0±9.7% and 48.6±12.4%, respectively (Fig. 4). The 
overall event-free survival rate was not different between pa-
tients with echocardiographic type I and those with type II (p= 
0.61). There was no significant difference in the event-free sur-
vival rate between the patients with PM and ICD (p=0.12).
Discussion
The annual incidence of systemic sarcoidosis in the United 
States was reported to as approximately 20 per 100,000.
11) In 
Korea, systemic sarcoidosis is also a rare disease but the inci-
dence has gradually increased from 14 cases in 1993 (0.027 
per 100,000) to 59 cases in 1998 (0.125 per 100,000).
12) With 
regard to the prevalence of cardiac involvement, there is a 
significant racial difference. About 20-27% of systemic sar-
coidosis patients presented with cardiac involvement in the 
United States, however the proportion was 58% in Japan.
13) 
In one Korean study of 309 patients with pathologically pro-
ven systemic sarcoidosis, the prevalence of cardiac sarcoido-
sis was only 0.7%.
12) We understand those reflect the difficul-
ty in assessing cardiac involvement. According to the land-
mark report on cardiac sarcoidosis, which confirmed that 
most patients with cardiac sarcoidosis have little or no clini-
cal evidence of extra-cardiac organ dysfunction,
5) the current 
guideline for definitive diagnosis of sarcoidosis needs to be ch-
anged, especially for cardiac sarcoidosis. This is sensible, con-
sidering the low yield of endomyocardial biopsy.
The systemic manifestations of sarcoidosis are quite diverse. 
Occasionally, it first comes to attention when abnormalities 
are detected on a chest radiograph during routine screening. 
Fig. 4. Event free survival of the overall group (A), and comparisons 
with those according to echocardiographic type (B), and the class 
of cardiac device inserted (C). Adverse clinical events included dea-
th, cardiac transplantation, and hospital admission due to cardiac 
causes during the follow-up period. ICD: implantable cardioverter-
defibrillator, PM: pacemaker.
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The majority of these patients are asymptomatic, whereas up 
to a third of patients have symptom related to organ impair-
ment.
14) Constitutional symptoms, such as fatigue, night sw-
eats, and weight loss are also common. Even in cases with car-
diac involvement, the clinical manifestation is non-specific. 
It can manifest as cardiomyopathy with loss of muscle func-
tion, or tachyarrhythmias and bradyarrhythmias.
15)16) Alth-
ough the clinical manifestation of cardiac involvement is ev-
ident in less than 5% of patients with cardiac involvement, 
once the manifestation is clinically overt, it is the major cause 
of death together with neurologic involvement and pulmo-
nary fibrosis.
6) 
In general, the diagnosis of sarcoidosis is established by 
histologic evidence in one or more organs with non-caseat-
ing epithelioid-cell granulomas.
17) Pathologic specimens sh-
ould be widely obtained where possible, such as the skin, 
peripheral lymph nodes, lacrimal glands, and the conjuncti-
va. According to one report, the diagnostic yield of transbr-
onchial biopsy by means of bronchoscopy reached at least 
85%, when multiple lung segments are sampled.
18) Unfortu-
nately, endomyocardial biopsy has a low diagnostic yield (less 
than 20%) because cardiac involvement tends to be patchy, 
and granulomas are more likely to be located in the left ven-
tricle and in the basal ventricular septum, than in the right 
ventricle, where endomyocardial biopsies are usually per-
formed.
16) Failure to demonstrate histologic evidence of car-
diac sarcoidosis in all 6 patients who underwent endomyo-
cardial biopsy in our study represents the pitfalls of pathologic 
diagnosis of cardiac sarcoidosis. Although isolated cardiac 
involvement with sarcoidosis is known to be extremely rare 
(previously three cases were described by Nelson et al.
19)), one 
peculiar observation in our study was that there were only 3 
patients with extracardiac involvement, and the other 18 
presented disease limited to the heart. In this context, patho-
logic confirmation from extracardiac organ was also chal-
lenging.
Patients with cardiac sarcoidosis showed very poor long-
term event-free survival rates,
20) which was confirmed again 
in our study. Different arrhythmias were observed during fol-
low-up and ICD was necessary to manage VT in several pa-
tients during follow-up after PM insertion.
Considering the low yield of endomyocardial biopsy and 
rare systemic involvement in patients with cardiac sarcoido-
sis, we need different approaches to diagnose high-risk pati-
ents, including those who underwent device treatment for ar-
rhythmias. We believe that echocardiographic findings can 
be useful for this purpose in this selected group of patients, be-
cause characteristic basal septal thinning or aneurysmal dil-
atation can be regarded as supporting evidence of cardiac 
involvement of sarcoidosis.
21) The clinical impact of cardiac sar-
coidosis based on a combination of clinical features of signi-
ficant arrhythmias warranting device therapy and character-
istic echocardiographic findings needs to be evaluated in fu-
ture investigations.
The main limitation of our study is that pathologic confir-
mation was not possible in all patients with characteristic 
echocardiographic findings. Although we ruled out the pos-
sibility of significant coronary artery disease as a cause of the 
characteristic wall motion abnormalities, we were not com-
pletely certain that other infiltrative or myocardial disorders 
resulted in these echocardiographic findings.
22) The other 
limitation is that we selected patients with serious arrhyth-
mias warranting device treatment, which significantly con-
tributes to selection bias. Thus, the prevalence of characteris-
tic echocardiographic findings in these selected patients does 
not necessarily represent the true prevalence of cardiac sar-
coidosis.
In conclusion, in this observational study, we have found 
that some patients who received device therapy to control 
serious arrhythmias, including PM and ICD, showed char-
acteristic echocardiographic features, such as thinning of 
basal septum or aneurysmal change without significant cor-
onary artery disease, suggestive of cardiac sarcoidosis. These 
patients were characterized by very low endomyocardial bio-
psy yield and rare non-cardiac involvement. As these patients 
showed low event-free survival rates, combination of clinical 
features and characteristic echocardiographic findings can 
be considered a rational approach for tentative diagnosis of 
cardiac sarcoidosis. The impact of this practical approach 
needs to be evaluated in future studies.
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